BBOT Stock Analysis: Buy, Sell, or Hold?
BBOT - BridgeBio Oncology Therapeutics, Inc. Common Stock
$8.11
0.31 (3.97%)
▲
5d:
+5.46%
30d:
-1.93%
90d:
-10.19%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When BBOT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: BBOT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: BBOT shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: BBOT is currently trading at $8.11, which is considered slightly high relative to its 30-day fair value range of $7.42 to $8.34.
Technical Outlook: Technically, BBOT is in a strong downtrend. The price is approaching resistance at $8.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: BBOT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.11 (+209.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BBOT is in a strong downtrend. The price is approaching resistance at $8.29. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: BBOT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $25.11 (+209.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$7.42 -
$8.34
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 209.6% below Wall St target ($25.11)
Trading Range Analysis
30-Day Trading Range
$7.42 -
$8.34
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$7.29
Resistance Level
$8.29
Current Trend
Strong Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.82
Wall Street Target
$25.11
(+209.6%)
Share & Embed Analysis
Last updated: July 02, 2026 10:47 PM ET
Data refreshes hourly during market hours. Next update: 11:47 PM
Data refreshes hourly during market hours. Next update: 11:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BBOT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$106 | 64 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 54 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$110 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 45 HOLD |
